1
Scola Paul Michael, Mcphee Fiona, Meanwell Nicholas A, Hewawasam Piyasena, Campbell Jeffrey Allen: Hepatitis c virus inhibitors. Bristol Myers Squibb Company, Scola Paul Michael, Mcphee Fiona, Meanwell Nicholas A, Hewawasam Piyasena, Campbell Jeffrey Allen, VOLLES Warren K, May 26, 2005: WO/2005/046712 (101 worldwide citation)

Compounds are disclosed having general formula (I), wherein R1, R2, R3, R4, R', B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.


2
Xiangdong Alan Wang, Li Qiang Sun, Sing Yuen Sit, Ny Sin, Paul Michael Scola, Piyasena Hewawasam, Andrew Charles Good, Yan Chen, Jeffrey Allen Campbell: Hepatitis C virus inhibitors. Bristol Myers Squibb Company, Warren K Volles, February 7, 2006: US06995174 (89 worldwide citation)

Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R′, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.


3

4
Ripka Amy, Campbell Jeffrey Allen, Good Andrew Charles, Scola Paul Michael, Sin Ny, Venables Brian: Hepatitis c virus inhibitors. Bristol Myers Squibb Company, Ripka Amy, Campbell Jeffrey Allen, Good Andrew Charles, Scola Paul Michael, Sin Ny, Venables Brian, VOLLES Warren K, April 22, 2004: WO/2004/032827 (82 worldwide citation)

The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in t ...


5

6

7

8
Scola Paul Michael, Campbell Jeffrey Allen, Sin Ny, Sun Li Qiang, Wang Xiangdong Alan: Hepatitis c virus inhibitors. Bristol Myers Squibb Company, Scola Paul Michael, Campbell Jeffrey Allen, Sin Ny, Sun Li Qiang, Wang Xiangdong Alan, VOLLES Warren K, June 9, 2005: WO/2005/051410 (75 worldwide citation)

Hepatitis C virus inhibitors are disclosed having the general formula (I) wherein A, R2, R3, R', B and Y are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.


9
LOPEZ OMAR D: Hepatitis c virus inhibitors. BRISTOL MYERS SQUIBB COMPANY, Mingo Pamela A, December 2, 2010: WO/2010/138368 (73 worldwide citation)

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.


10